Although RARRES2 has different expression patterns in different tumors, RARRES2 can promote GBM mesenchymal properties by inhibiting the ubiquitin‒proteasome degradation of CMKLR1 [42], which indicates that RARRES2 can support tumor progression in GBM. This evidence concerns the gene CMKLR1 and glioblastoma.